Phathom Pharmaceuticals ^{Priced, Nasdaq: PHAT}

We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori infection. Takeda Pharmaceutical developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500 million in net sales in its fourth full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the US, European, and Canadian rights to vonoprazan from Takeda. We believe we can leverage Takeda’s extensive clinical data to advance vonoprazan through pivotal trials in the US and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive GERD and a second for the treatment of H. pylori infection. We expect to report top-line data from both trials in 2021.